CheckMate 204 Study

John Fruehauf, MD of UC Irvine Health discusses new first-line therapy for asymptomatic melanoma brain metastases.

 

 

 

 

new first-line therapy, asymptomatic melanoma brain metastases, uc irvine health, checkmate 204 study, study, checkmate 204